The U.S. Food and Drug Administration granted an orphan drug designation to Changchun High-Tech Industry's (SHE:000661) unit, Changchun GeneScience Pharmaceutical, for its GenSci128 tablets as a treatment for pancreatic cancer, according to a Wednesday filing on the Shenzhen bourse.
The designation will help facilitate the subsequent development and review of the Chinese drugmaker's drug in the U.S. for the indicated cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.